Armata Pharmaceuticals, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
AMEX
Deborah Birx, Chief Executive Officer and a Director of Armata Pharmaceuticals, Inc., reported a transaction in 14,041 shares of common stock on July 10, 2026.
AMEX
Armata Pharmaceuticals, Inc. director Daniel B. Gilmer reported the acquisition of stock options for 51,280 shares.
AMEX
Armata Pharmaceuticals' Chief Business Officer, Pierre Kyme, reported the disposition of 1,030 common shares to cover tax liabilities related to restricted stock unit vesting.
AMEX
Armata Pharmaceuticals CEO Deborah Birx reported the sale of 4,919 common shares to cover tax obligations related to restricted stock unit settlement.
AMEX
Armata Pharmaceuticals Director Robin Kramer received a grant of 25,640 stock options with an exercise price of $11.61, vesting fully on March 9, 2027.
AMEX
Armata Pharmaceuticals' Chief Business Officer, Pierre Kyme, was granted 183,142 stock options with an exercise price of $11.61, vesting over four years.
AMEX
David Duane House, SVP of Finance and PFO at Armata Pharmaceuticals, was granted 109,885 stock options with a vesting schedule tied to continuous service.
AMEX
Armata Pharmaceuticals Director Joseph M. Patti reported the acquisition of 25,640 stock options with an exercise price of $11.61, set to vest fully by March 9, 2027.
AMEX
Armata Pharmaceuticals, Inc. Director Todd C. Peterson was granted 25,640 stock options with an exercise price of $11.61, vesting fully on March 9, 2027.
AMEX
Armata Pharmaceuticals director Odysseas Kostas D received 25,640 stock options with an exercise price of $11.61, vesting in March 2027.
AMEX
Armata Pharmaceuticals, Inc. CEO Deborah Birx was granted 421,226 stock options with a vesting schedule over four years, as disclosed in a recent SEC Form 4 filing.
AMEX
Armata Pharmaceuticals Director Sarah J. Schlesinger was granted 25,640 stock options with an exercise price of $11.61, vesting fully on March 9, 2027.
AMEX
Armata Pharmaceuticals Director Jules Haimovitz received a grant of 25,640 stock options with an exercise price of $11.61, vesting in March 2027.
AMEX
Armata Pharmaceuticals, Inc. CEO Deborah Birx reported the disposition of 13,637 common shares at $2.27 each for tax withholding purposes related to restricted stock units.
AMEX
Deborah Birx, CEO of Armata Pharmaceuticals, reports disposing of shares to cover income tax obligations related to the settlement of restricted stock units.
AMEX
Chief Business Officer Pierre Kyme of Armata Pharmaceuticals reports disposing of 1,027 shares to cover income tax obligations related to restricted stock units.
AMEX
Director Odysseas Kostas D. of Armata Pharmaceuticals acquired stock options on February 5, 2025.
AMEX
Director Sarah J. Schlesinger acquired 54,343 stock options in Armata Pharmaceuticals, Inc. on February 5, 2025.
AMEX
Todd C. Peterson, a director of Armata Pharmaceuticals, Inc., acquired stock options on February 5, 2025.
AMEX
Joseph M. Patti, a director of Armata Pharmaceuticals, Inc., reports the acquisition of stock options.
AMEX
Pierre Kyme, Chief Business Officer of Armata Pharmaceuticals, reports the acquisition of stock options.
AMEX
Robin Kramer, a director of Armata Pharmaceuticals, Inc., reported the acquisition of stock options.
AMEX
David Duane House, SVP, Finance, and PFO of Armata Pharmaceuticals, Inc., reports the acquisition of stock options.
AMEX
Jules Haimovitz, a director of Armata Pharmaceuticals, acquired stock options exercisable for 54,343 shares of common stock on February 5, 2025.
AMEX
Deborah Birx, CEO of Armata Pharmaceuticals, acquired 240,000 stock options on February 5, 2025, according to a Form 4 filing.
AMEX
Form 4: Armata Pharmaceuticals SVP, Finance, and PFO David Duane House Acquires 75,000 Stock Options
David Duane House, SVP, Finance, and PFO of Armata Pharmaceuticals, acquired 75,000 stock options on October 2, 2024.
AMEX
Director Joseph M. Patti reports acquisition of stock options in Armata Pharmaceuticals.
AMEX
Director Robin Kramer reports acquisition of stock options in Armata Pharmaceuticals.
AMEX
Todd C. Peterson, a director of Armata Pharmaceuticals, acquired stock options on March 14, 2024.
AMEX
Richard Rychlik, Corporate Controller and PFO of Armata Pharmaceuticals, reports acquisition of common stock and stock options.